doi: 10.3389/FIMMU.2018.02939/BIBTEX 180 ValentaRHochwallnerHLinhartBPahrS
Its tri-agonist design delivers synchronized receptor activation that enables streamlined protocols for: Unlike single-pathway peptides or even dual-agonists, Trinity-X uniquely merges GLP-1, GIP, and glucagon receptor activities into one stable compound
We default to the most natural cocktail available and add medications when necessary
It is not scheduled as a controlled substance by the DEA and is not explicitly named in the Designer Anabolic Steroid Control Act of 2014, though federal prosecutors have pursued unapproved-new-drug and misbranding cases against vendors marketing peptides for human performance use
Pascual A, Hidalgo-Figueroa M, Gmez-Daz R, Lpez-Barneo J
Brighten up with 5% highly-concentrated Glutathione